Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
LIVN

LIVN - LivaNova PLC Stock Price, Fair Value and News

52.69USD+0.40 (+0.76%)Market Closed

Market Summary

LIVN
USD52.69+0.40
Market Closed
0.76%

LIVN Alerts

  • 1 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

LIVN Stock Price

View Fullscreen

LIVN RSI Chart

LIVN Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-89.82

Price/Sales (Trailing)

2.41

EV/EBITDA

-81.08

Price/Free Cashflow

93.72

LIVN Price/Sales (Trailing)

LIVN Profitability

EBT Margin

-10.56%

Return on Equity

-2.6%

Return on Assets

-1.29%

Free Cashflow Yield

1.07%

LIVN Fundamentals

LIVN Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

11.96%

Rev. Growth (Qtr)

-4.91%

LIVN Earnings

Earnings (TTM)

-31.8M

Earnings Growth (Yr)

-669.1%

Earnings Growth (Qtr)

-356.7%

Breaking Down LIVN Revenue

Last 7 days

-1.3%

Last 30 days

-16.6%

Last 90 days

4.1%

Trailing 12 Months

8.9%

How does LIVN drawdown profile look like?

LIVN Financial Health

Current Ratio

3.17

Debt/Equity

0.5

Debt/Cashflow

0.11

LIVN Investor Care

Shares Dilution (1Y)

0.71%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.2B000
20231.0B1.1B1.1B1.2B
20221.0B1.0B1.0B1.0B
2021939.4M1.0B1.0B1.0B
20201.1B980.8M952.3M934.2M
20191.1B1.1B1.1B1.1B
20181.0B1.1B1.1B1.1B
2017782.5M799.8M983.6M1.0B
2016640.9M811.4M982.4M782.7M
2015253.7M255.8M263.4M294.7M
2014275.1M282.0M285.1M288.5M
20130254.3M261.2M268.2M

Tracking the Latest Insider Buys and Sells of LivaNova PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
moore daniel jeffrey
acquired
3,249,590
57.39
56,623
-
Jun 03, 2024
moore daniel jeffrey
sold
-3,403,690
60.1115
-56,623
-
Mar 30, 2024
hebbelinck trui
sold (taxes)
-309,964
55.94
-5,541
chief human resources officer
Mar 30, 2024
bolton stephanie
sold (taxes)
-203,789
55.94
-3,643
president, global epilepsy
Mar 30, 2024
shvartsburg alex
sold (taxes)
-352,981
55.94
-6,310
cfo
Mar 30, 2024
hutchinson michael damon
acquired
-
-
1,478
chief legal officer
Mar 30, 2024
shvartsburg alex
acquired
-
-
14,752
cfo
Mar 30, 2024
bolton stephanie
acquired
-
-
7,744
president, global epilepsy
Mar 30, 2024
hutchinson michael damon
sold (taxes)
-30,319
55.94
-542
chief legal officer
Mar 30, 2024
hebbelinck trui
acquired
-
-
11,779
chief human resources officer

1–10 of 50

Which funds bought or sold LIVN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
800
901
1,004
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-34.17
-492,000
1,157,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
78,000
1,028,000
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.3
70,399
3,016,060
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-70.77
-7,133,190
3,295,370
-%
May 15, 2024
Parallax Volatility Advisers, L.P.
new
-
1,088,420
1,088,420
-%
May 15, 2024
CITADEL ADVISORS LLC
added
26.1
21,639,700
81,198,300
0.02%
May 15, 2024
Brevan Howard Capital Management LP
sold off
-100
-912,590
-
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-12.88
-1,662,370
26,936,500
-%
May 15, 2024
Redmile Group, LLC
reduced
-8.73
-778,485
58,053,400
2.13%

1–10 of 42

Are Funds Buying or Selling LIVN?

Are funds buying LIVN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LIVN
No. of Funds

Unveiling LivaNova PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 17, 2024
integrated core strategies (us) llc
5.1%
2,733,440
SC 13G
Feb 12, 2024
primecap management co/ca/
10.75%
5,791,280
SC 13G/A
Jan 23, 2024
blackrock inc.
13.8%
7,415,557
SC 13G/A
May 09, 2023
primecap management co/ca/
10.07%
5,394,100
SC 13G/A
Feb 14, 2023
harris associates l p
3.8%
2,008,159
SC 13G/A
Feb 09, 2023
primecap management co/ca/
8.58%
4,594,917
SC 13G/A
Jan 26, 2023
blackrock inc.
12.8%
6,834,335
SC 13G/A
Jan 20, 2023
blackrock inc.
12.8%
6,834,335
SC 13G/A
Feb 11, 2022
harris associates l p
7.2%
3,823,266
SC 13G/A
Feb 10, 2022
primecap management co/ca/
8.3%
4,415,445
SC 13G/A

Recent SEC filings of LivaNova PLC

View All Filings
Date Filed Form Type Document
Jun 13, 2024
S-8
Employee Benefits Plan
Jun 12, 2024
8-K
Current Report
Jun 06, 2024
DEFA14A
DEFA14A
Jun 05, 2024
4
Insider Trading
Jun 03, 2024
144
Notice of Insider Sale Intent
May 31, 2024
SD
SD
May 17, 2024
3
Insider Trading
May 03, 2024
10-Q
Quarterly Report
May 03, 2024
IRANNOTICE
IRANNOTICE
May 01, 2024
8-K
Current Report

Peers (Alternatives to LivaNova PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
40.3B
-0.87% -1.28%
32.05
4.47
-2.84% -3.00%
67.6B
19.7B
-1.49% -8.74%
50.68
3.43
4.82% -17.56%
19.3B
3.9B
-8.68% -23.17%
41.69
4.92
5.72% 46.72%
17.2B
14.9B
-4.71% -24.07%
6.49
1.16
2.98% 207.68%
MID-CAP
9.6B
3.5B
-1.72% 24.73%
30.66
2.71
6.16% 35.06%
8.4B
12.4B
-11.97% -13.19%
21.71
0.68
-0.93% -18.83%
8.1B
2.6B
-6.15% -25.48%
-24.99
3.09
-6.25% -68.58%
5.4B
3.9B
-7.61% -31.99%
-56.77
1.38
0.23% 90.80%
3.4B
387.1M
-0.71% 28.31%
-215.21
8.86
30.82% 65.57%
2.0B
6.6B
-12.43% -18.98%
10.47
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
15.14% 13.53%
-2.17
0.46
7.94% -1695.32%
390.3M
169.3M
0.92% -1.83%
-5.08
2.31
7.49% -244.90%
246.7M
324.0M
-3.14% -43.23%
-1.28
0.76
-3.19% -337.41%
50.2M
50.5M
2.84% -79.14%
-2.2
1
14.25% -10.06%
1.8M
3.7M
75.00% -80.56%
-0.15
0.49
5.77% 8.23%

LivaNova PLC News

Latest updates
Yahoo New Zealand News8 hours ago
Simply Wall St13 Jun 202403:02 pm
Defense World10 Jun 202409:22 am
Defense World09 Jun 202411:38 am

LivaNova PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.9%295310286294263275253254240270253264248270240182242288269277251
Gross Profit9.1%207190202205174184171184168202169172163167148115165193---
  S&GA Expenses-2.6%130133135126124120115116119124109123116117104103120153123127126
  R&D Expenses-1.1%46.0046.0047.0051.0050.0045.0036.0034.0041.0044.0042.0053.0045.0044.0047.0025.0036.0023.0046.0035.0044.00
EBITDA Margin-1699.5%-0.03*0.00*0.09*-0.01*0.01*0.00*-0.02*0.04*-0.02*-0.05*-0.33*-0.30*---------
Interest Expenses1.7%16.0016.0015.0015.0013.0013.0013.0014.008.006.0011.0017.0016.0016.0015.006.005.005.005.004.002.00
Income Taxes107.0%8.00-1105.004.002.005.001.003.003.003.002.004.003.00-18.54-3.9966.00-44.71-6.94-10.65-6.16-6.61
Earnings Before Taxes63.7%-34.20-94.30-1.985.0010.006.00-10619.006.00-2.30-41.56-52.54-28.08-301-18.71-21.66-6.01-15221.00-35.56-21.46
EBT Margin-50.0%-0.11*-0.07*0.02*-0.08*-0.07*-0.07*-0.08*-0.02*-0.09*-0.12*-0.41*-0.39*---------
Net Income-356.7%-41.9416.00-7.321.007.002.00-10716.003.00-5.13-43.44-56.49-30.76-281-14.81-89.4136.00-14332.00-29.21-14.85
Net Income Margin-276.2%-0.03*0.02*0.00*-0.09*-0.08*-0.08*-0.09*-0.03*-0.10*-0.13*-0.40*-0.37*---------
Free Cashflow-91.3%4.0041.009.00-23.6013.0010.0030.00-16.3721.0026.0021.0019.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets1.2%2,4602,4302,3292,3422,2952,2952,2132,3362,4172,2012,2032,3972,3692,4002,5222,5032,4542,4122,5102,6222,600
  Current Assets5.2%1,040988954942903886851772810679646809691708673672617549547568541
    Cash Equivalents16.0%30926723422352351650640744220818232925325322823312661.0075.0045.0051.00
  Inventory3.6%153148162156142129122119115106124127125115178177170164168169161
  Net PPE-1.3%152154149150149147139143148150153157158164191186184181180185186
  Goodwill-1.4%772783767779774769742898897900905918910922918902889916946962952
Liabilities7.5%1,2381,1521,1041,1011,0681,0871,0661,0541,1259068911,3561,3031,2911,1711,1691,0621,0281,0151,1381,113
  Current Liabilities-2.2%328335295288316297288264308697658702295309282268530513469596622
  Long Term Debt6.4%60556956856852051851846045610.0011.00431646642637639316260273174142
    LT Debt, Current9.1%19.0017.00------------------23.00
    LT Debt, Non Current6.4%60556956856852051851846045610.0011.00431646642637639316260273174142
Shareholder's Equity-4.4%1,2221,2781,2251,2411,2271,2081,1471,2821,2921,2951,2991,0291,0551,1091,3511,3331,3931,3781,4951,4831,487
  Retained Earnings-4.3%-1,008-966-982-975-976-984-985-878-894-897-879-837-782-761-472-457-369-406-263-295-266
  Additional Paid-In Capital0.1%2,1932,1902,1812,1692,1632,1582,1442,1332,1212,1182,1071,7791,7701,7681,7581,7511,7401,7351,7251,7171,707
Shares Outstanding0.4%54.0054.0054.0054.0054.0054.0053.0053.0053.0051.0050.0049.00---------
Float----2,800---3,300---4,100---2,300---3,500-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-81.5%9,98153,95818,136-17,93720,75718,70335,638-10,24325,82333,48023,95325,63119,48036,9858,657-19,019-106,0452,866-76,587-19,3951,974
  Share Based Compensation23.5%10,2268,28311,7795,71110,57912,31710,72711,50910,2569,99011,1229,9169,5368,2447,8119,9919,0438,4268,5318,7246,872
Cashflow From Investing47.6%-6,363-12,138-10,054-6,655-11,484-10,953-5,831-16,148-5,482-3,631-6,18056,573-9,858-8,507-10,671-11,581-11,085-10,771-8,065-16,813-5,641
Cashflow From Financing840.3%37,147-5,018-4,27736,014-5,235-1,65773,230-6,320214,877-3,300-164,096-5,759-8,328-5,171-3,770136,604183,093-7,160116,68429,4687,589
  Buy Backs----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LIVN Income Statement

2024-03-31
Condensed Consolidated Statements of (Loss) Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net revenue$ 294,912$ 263,418
Cost of sales87,52289,335
Gross profit207,390174,083
Operating expenses:  
Selling, general and administrative129,863124,129
Research and development45,66449,986
Other operating expenses15,6172,310
Operating income (loss)16,246(2,342)
Interest expense(15,893)(13,437)
Loss on debt extinguishment(25,482)0
Foreign exchange and other income/(expense)(9,071)25,547
(Loss) income before tax(34,200)9,768
Income tax expense7,7172,371
Loss from equity method investments(26)(27)
Net (loss) income$ (41,943)$ 7,370
Basic (loss) income per share (in dollars per share)$ (0.78)$ 0.14
Diluted (loss) income per share (in dollars per share)$ (0.78)$ 0.14
Shares used in computing basic (loss) income per share (in shares)54,00853,617
Shares used in computing diluted (loss) income per share (in shares)54,00853,900

LIVN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current Assets:  
Cash and cash equivalents$ 309,191$ 266,504
Restricted cash306,492311,368
Accounts receivable, net of allowance of $11,026 at March 31, 2024 and $12,019 at December 31, 2023209,431215,072
Inventories153,176147,887
Prepaid and refundable taxes22,54320,145
Prepaid expenses and other current assets39,18427,182
Total Current Assets1,040,017988,158
Property, plant and equipment, net152,237154,181
Goodwill771,817782,941
Intangible assets, net253,927261,178
Operating lease assets50,26050,845
Investments22,67522,843
Deferred tax assets113,687118,858
Long-term derivative assets41,61738,496
Other assets13,36512,063
Total Assets2,459,6022,429,563
Current Liabilities:  
Current debt obligations19,70418,111
Accounts payable75,94480,845
Accrued liabilities and other94,029107,301
Current litigation provision liability16,98010,756
Taxes payable29,76123,340
Accrued employee compensation and related benefits91,35394,630
Total Current Liabilities327,771334,983
Long-term debt obligations604,753568,543
Contingent consideration80,76980,902
Deferred tax liabilities10,97411,567
Long-term operating lease liabilities43,72445,388
Long-term employee compensation and related benefits17,06217,254
Long-term derivative liabilities104,92045,569
Other long-term liabilities48,09247,729
Total Liabilities1,238,0651,151,935
Commitments and Contingencies
Stockholders’ Equity:  
Ordinary Shares, £1.00 par value: unlimited shares authorized; 54,295,837 shares issued and 54,148,808 shares outstanding at March 31, 2024; 53,942,151 shares issued and 53,918,222 shares outstanding at December 31, 202382,97582,533
Additional paid-in capital2,192,6762,189,517
Accumulated other comprehensive loss(45,206)(27,883)
Accumulated deficit(1,008,427)(966,484)
Treasury stock at cost, 147,029 ordinary shares at March 31, 2024; 23,929 ordinary shares at December 31, 2023(481)(55)
Total Stockholders’ Equity1,221,5371,277,628
Total Liabilities and Stockholders’ Equity$ 2,459,602$ 2,429,563
LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
 CEO
 WEBSITElivanova.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES2900

LivaNova PLC Frequently Asked Questions


What is the ticker symbol for LivaNova PLC? What does LIVN stand for in stocks?

LIVN is the stock ticker symbol of LivaNova PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LivaNova PLC (LIVN)?

As of Fri Jun 14 2024, market cap of LivaNova PLC is 2.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers. The fair value of LivaNova PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LivaNova PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LivaNova PLC a good stock to buy?

The fair value guage provides a quick view whether LIVN is over valued or under valued. Whether LivaNova PLC is cheap or expensive depends on the assumptions which impact LivaNova PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIVN.

What is LivaNova PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, LIVN's PE ratio (Price to Earnings) is -89.82 and Price to Sales (PS) ratio is 2.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIVN PE ratio will change depending on the future growth rate expectations of investors.